Analysis for any development stage, spanning from biomarker discovery through to CDx development. Benefit from our global network of pathologists and validated singleplex, multiplex, and hyperplex assays.
Our extensive experience and cutting-edge technologies ensure quality and consistency everytime.
Global, In-House Pathologists
Global Network, One QMS
Custom Assay Development
Registrational Trial Support
Integrated ML/AI solutions
Unlock the full value of multiplex immunofluorescence data with SPARTA (Spatial Phenotyping and Analysis in Regions of Tissue with AI), CellCarta’s framework for mIF analysis. SPARTA standardizes how datasets are processed and analyzed across imaging systems to easily extract meaningful insights.
